APE1 /Ref‐1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles
Physiological Reports · 2025
DOI: 10.14814/phy2.70494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2025. Verfasst von Hannah Lalunio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: DNA-(Apurinic or Apyrimidinic Site) Lyase, Macrophages, Muscular Dystrophy, Duchenne, Muscle, Skeletal. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic inflammation and oxidative stress exacerbate muscle wasting and weakness in Duchenne muscular dystrophy (DMD). Apurinic/apyrimidinic endonuclease 1/redox factor‐1 (APE1/Ref‐1) regulates transcription factors involved in inflammatory and oxidative stress pathways. APE1/Ref‐1 is an emerging therapeutic target in inflammatory conditions. This study aimed to investigate the effects of APX3330, a small molecule inhibitor of APE1's Ref‐1 on mdx mouse pathology, a model of DMD. Six‐week‐old mdx mice and wild type (WT) C57Bl/10 mice were treated with APX3330 (25 mg·kg −1 ) or vehicle for 6 weeks. Ex vivo contractile function, histological and biochemical analysis were performed in extensor digitorum longus (EDL) and soleus muscles. APE1/Ref‐1 protein was greater in mdx hindlimb muscles compared to WT ( p < 0.0001) and APE1/Ref‐1 protein abundance was not altered by treatment with APX3330. In dystrophic EDL muscles, APX3330 treated mice had fewer (47%) infiltrating CD68‐positive monocytes/macrophages ( p < 0.05) compared to vehicle‐treated mdx mice. Markers of oxidative stress, NRF2/KEAP‐1, were unchanged, yet phospho‐NF‐κB abundance was higher with treatment ( p < 0.01). APX3330 treatment neither improve force output and fatiguability of isolated hindlimb muscles, nor affect muscle pathology. As APE1/Ref‐1 inhibition modestly lowered inflammation, with no improved contractile function, targeting solely inflammation and oxidative stress in 6‐week‐old mdx mice appears insufficient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
- Australian Institute for Musculoskeletal Science (AIMSS), Victoria University, Melbourne, Victoria, Australia.
- Institute of Health and Sport (IHeS), Victoria University, Melbourne, Victoria, Australia.
- Centre for Muscle Research, The University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Alan Hayes
Zitieren
APA
Lalunio, H., Goodman, C. A., Stupka, N., Giourmas, N., Debruin, D. A., Sahakian, L., Nurgali, K., & Hayes, A. (2025). APE1 /Ref‐1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles. Physiological Reports. https://doi.org/10.14814/phy2.70494
Vancouver
Lalunio H, Goodman CA, Stupka N, Giourmas N, Debruin DA, Sahakian L, et al. APE1 /Ref‐1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles. Physiological Reports. 2025. doi:10.14814/phy2.70494
BibTeX
@article{Lalunio2025,
author = {Lalunio, Hannah and Goodman, Craig A and Stupka, Nicole and Giourmas, Nicholas and Debruin, Danielle A and Sahakian, Lauren and Nurgali, Kulmira and Hayes, Alan},
title = {APE1 /Ref‐1 inhibition via APX3330 lowers monocyte/macrophage infiltration without ameliorating the structure and function of dystrophic mdx hindlimb muscles},
journal = {Physiological Reports},
year = {2025},
doi = {10.14814/phy2.70494}
}
EUVIMED